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Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321 S303(HR: 1.78, 95% CI: 0.98-3.23; P¼0.058) compared with MRD
and (HR: 2.30, 95% CI: 1.26-4.21; P¼0.007) with MUD.
Conclusions: 1) Among CMV R+ TCD recipients, the inci-
dence of CMV viremia was 79%. 2) In multivariate analysis,
CMV D- with decreased risk for CMV viremia compared to
D+. 3) Diagnosis of multiple myeloma and allografts from
mismatched donor was associated with increased risk. 4)
Further studies are needed to assess the effect of CMV
donor serostatus in transplant outcomes in TCD. If vali-
dated in larger cohorts, our ﬁndings have implications for
donor selection and targeted strategies for CMV pre-
vention.435
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Background: Fulminant disseminated toxoplasmosis (FTX)
is a rare complication of allogeneic SCT with an incidence
ranging from 1-8% based on endemicity. Plasma quantita-
tive PCR (qPCR) affords rapid diagnosis. Before 2011, pa-
tients (pts) at MSK received pre-SCT TMP/SMZ (T/S) for
Pneumocystis (PCP) prophylaxis (ppx). Pts with positive (+)
toxo IgG (R+) or from + donors (D+) received Atovaquone
(ATQ) ppx starting day (d) 30-50 post SCT. The incidence of
toxoplasmosis was 0-1 cases/year. In 2011, T/S ppx pre-SCT
was limited to pts at high risk for PCP. From January
through June 2013 we observed a cluster of 4 cases of FTX.
Since July 2013, we have, therefore, implemented “aggres-
sive” ppx.
Methods: We compared the incidence of FTX in adult re-
cipients of peripheral blood CD34+ selected (TCD) or CB al-
lografts for hematologic malignancies from May 2012
through June 2013 (Period A) and from July 2013 through
August 2014 (Period B). R+ includes positive or equivocal
toxo IgG. PPX: In Period A, R+ or D+ received ATQ ppx starting
on d +30-50 post-SCT with no routine qPCR monitoring. In
Period B “aggressive” ppx consisted of T/S pre-SCT and ATQ
starting on d +14. qPCR was checked at least weekly from d+
14 to 60 and as needed thereafter. In Periods A and B, qPCR
was ordered in symptomatic pts at clinician’s discretion. FTX
cases are deﬁned as positive qPCR with fulminant course and
no alternative explanation.
Results: During Period A, 154 (114 TCD, 40 CB) pts had SCT
including 19 (12.3%) R+. During Period B, 144 (118 TCD, 26
CB) pts had a SCT including 20 (13.9%) R+. In Period A, 4/
154 (2.6%) pts had FTX vs. 0/144 (0%) pts in Period B. In
period A, 3/19 (15.8%) R+ and 1 R-/D- pt had FTX. R+ cases
came from Turkey, Ukraine and West Africa, received TCD
(2) or CB (1) transplants from D- (3) for acute leukemia (2)
or multiple myeloma (1) and were diagnosed <60 days
post SCT. The fourth case was R-/D-, presented 5 months
after TCD SCT, after traveling to UK and Mexico. Three pts
presented with high fevers and 1 with multi-system
deterioration. All pts progressed to multi-organ failure and
expired within 7 days of presentation. At death qPCR
ranged 0.3-5.0x106 copies/ml. No autopsies were done. Aninvestigation for a shared nosocomial source was unre-
vealing. During Period B, 1/20 (5%) R+ had 2 positive qPCRs.
This pt was asymptomatic and noncompliant with ATQ
ppx. He was treated with T/S and subsequent PCRs were
negative. The diagnostic yield of qPCR was 0.76% (2 posi-
tives out of 264 qPCR performed).
Conclusions: 1) Toxoplasmosis infection should be imme-
diately considered in sero-positive TCD and CB SCT pts pre-
senting with fevers of unknown source. 2) We advocate early
and aggressive ppx in seropositive patients. 3) Routine
monitoring with qPCR should be strongly considered if
noncompliance or suboptimal absorption with ppx is sus-
pected. 4) Optimal preventive strategies for toxoplasmosis
have to be determined for each Center based on the patient
population.436
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Background/Aim: Low serum vitamin D levels are becoming
increasingly implicated in infections, pulmonary disorders,
cancer incidence and autoimmune conditions. Their role
in allogeneic hematopoietic stem cell transplantation
(alloHSCT) remains unclear, with some studies showing
deﬁciency to be associated with lower overall survival (OS)
and increased graft versus host disease (GVHD) rates, while
other studies show no differences in OS or GVHD rates. We
investigated the relationship between low vitamin D levels
pre-alloHSCT and post-transplant outcomes (OS, progres-
sion-free survival [PFS], non-relapse mortality [NRM],
relapse and acute and chronic GVHD).
Methods: We reviewed 492 alloHSCT recipients who had
pre-transplant vitamin D results available. Data on dates of
death, last follow-up, disease progression/relapse, disease
risk index (DRI) and acute and chronic GVHD status were
collected. Patients were categorized as replete (25-OH-Vit D
 50nmol/L or on replacement therapy) or deﬁcient (25-OH-
Vit D < 50nmol/L). Subgroup analysis was performed on B-
cell non-Hodgkin lymphoma patients (B-NHL).
Results: The vitamin D-deﬁcient cohort had a higher mor-
tality rate compared to the replete group. This reduction in
survival was maintained in the multivariate analysis (HR 1.5,
95% CI 1.1-2.0, P¼0.013). There were no signiﬁcant differ-
ences in NRM, PFS, acute/chronic GVHD, or relapse rates
between the two groups. No signiﬁcant differences were
noted with any of these outcomes in the 123 B-NHL patients.
There was no association between 25-OH-Vit D levels and
DRI.
Conclusion: Vitamin D deﬁciency appears associated with
increased mortality in alloHSCT recipients. The mechanisms
of this ﬁnding remain unclear. GVHD rates did not appear to
be affected by deﬁciency. Further research looking at
whether immunomodulatory effects of vitamin D are
responsible for the survival differences noted in our study,
and previously reported studies, is required.
